Articles from Paragonix Technologies

Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announced new lung preservation research at the 45th ISHLT Annual Meeting and Scientific Sessions. Drawing on data from the GUARDIAN-Lung Registry, the first and largest global clinical registry for studying lung preservation, investigators presented the largest analysis of the registry to date, demonstrating that Paragonix hypothermic preservation significantly reduced rehospitalizations and acute rejection after transplant.1

Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announces new research presented during the 45th ISHLT Annual Meeting and Scientific Sessions. The expansive study compared long-term outcomes of donor hearts preserved with the Paragonix SherpaPak® Cardiac Transport System, an FDA-cleared and CE-marked device, to those stored on conventional ice storage over four years post transplantation.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, today announced the launch of its OPO Expanded Lung Utilization Initiative - designed to increase lung utilization by providing Organ Procurement Organizations (OPOs) with access to its advanced BAROguard™ preservation device to enable rapid procurement of extended criteria donor lungs. Indiana Donor Network, based in Indianapolis, is among the first to participate in the program, and the first to successfully facilitate the transplantation of viable donor lungs that would have previously gone unrecovered. This collaborative effort led to the life-saving transplant of a recipient in Pennsylvania.

Paragonix Technologies, a leader in organ transplant technologies and services, today announced the successful completion of its hundredth case using the FDA-cleared KidneyVault™ Portable Renal Perfusion System. This milestone was achieved with the support of Tennessee Donor Services (TDS), an Organ Procurement Organization (OPO) that serves more than 6 million people across Tennessee and Virginia.

Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies of 2025. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 609 organizations across 58 sectors and regions.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today that five of its devices have now received approval under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. This approval further confirms Paragonix’s compliance with the highest quality control standards for medical devices and allows continued access to the European market under the new EU regulations.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the completion of the world’s first donor kidney transported utilizing commercial air travel while being continuously perfused in its FDA-cleared KidneyVault™ Portable Renal Perfusion System. This landmark case was facilitated by leading Organ Procurement Organization (OPO), Donor Network of Arizona (DNA), and the donor kidney was successfully transplanted at a transplant center in Texas.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the completion of the world’s first-in-human cases utilizing its FDA-cleared KidneyVault™ Portable Renal Perfusion System, marking a new chapter in kidney transplant preservation. These landmark cases included the successful transport of four donor kidneys to four separate medical institutions across the nation in a 24-hour period last December. The successful transplants were made possible through the support of leading OPOs (organ procurement organizations), including LifeGift of Houston, Texas.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the presentation of impactful clinical data on the use of its advanced organ preservation system, LIVERguard®, in a study presented at this year’s ASTS Winter Symposium. The study compares conventional ice static cold storage to the Paragonix LIVERguard system, using real-world multi-center data collected from the GUARDIAN-Liver Registry. The analysis illustrates that advanced liver preservation technology favorably influences post-transplant outcomes, including a statistically significant 27% reduction in acute kidney injury rates (p=0.016), a potentially life-threatening post-transplant complication.1 Additional data showed clinically impactful reductions in other common post-transplant complications, marking the results of the study an important development for liver transplant centers.

Paragonix Technologies is proud to announce they have joined the Living Donor Circle of Excellence. This program, an initiative from the American Society of Transplantation (AST), celebrates employers who implement internal policies that provide salary support to their employees who choose to be a living organ donor.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announces today its BAROguard® System has been recognized as one of TIME’s Best Inventions of 2024 in the medical care category. The annual list celebrates the top 200 innovations shaping the future, addressing critical challenges, and transforming lives across various fields, including healthcare, AI, and green energy.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, has successfully completed the world’s first-in-human case utilizing its newest donor organ preservation technology, the PancreasPak™ Organ Preservation System. The groundbreaking case, conducted by Dr. Matthew Hunter Witt of the Tampa General Hospital (TGH) Transplant Institute, safely protected a donor pancreas from donor to recipient. The PancreasPak™ System actively preserved and monitored the donor pancreas for almost 10 hours on its journey to provide a life-saving transplant.

Paragonix Technologies, a leader in organ preservation technology, and HonorBridge, North Carolina’s largest organ donation and tissue recovery organization, are proud to announce the successful transplantation of a donor liver to Tampa General Hospital using Paragonix’s state-of-the-art LIVERguard® technology. This achievement represents the first successful liver transplant facilitated by HonorBridge with Paragonix’s FDA-cleared advanced liver transport system.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, received U.S. Food and Drug Administration (FDA) 510(k) clearance for its donor kidney preservation system, KidneyVault. The KidneyVault System is Paragonix’s first perfusion device, integrating its streamlined digital monitoring capabilities with portable hypothermic perfusion technology to protect donor kidneys during transport and expand the donor pool. This novel combination of advanced technologies, the first of its kind in kidney transplant, further reinforces the company's ongoing commitment to improve and redefine the standard of care in transplant medicine. The additional FDA clearance makes Paragonix the only company with U.S. regulatory clearances for all five solid organs used in transplant procedures.

Paragonix Technologies, a leading organ transplant company, today announced the first lung transplant case in which a set of pediatric donor lungs were preserved using its BAROguard® Donor Lung Preservation System. The donor lungs were procured by Dr. Yuriy Stukov and Dr. Mohamad Aladaileah, and successfully transplanted by Dr. Mindaugas Rackauskas and Dr. Mark Bleiweis at UF Shands Children’s Hospital in Gainesville, Florida. BAROguard® received FDA 510(k) clearance in August 2023 and launched commercially in April 2024. This groundbreaking case was the innovative device’s first use in a pediatric setting.

Paragonix Technologies, a leading organ transplant company, today announces a significant milestone in the expansion of the GUARDIAN-Liver clinical registry, now bolstered by over 500 enrollments. In tandem with this growth, the company has appointed Dr. Kiran Dhanireddy, Vice President and Chief of the Tampa General Hospital (TGH) Transplant Institute, as the study's principal investigator. Dr. Dhanireddy’s esteemed leadership is set to further advance the evaluation of liver preservation and transport technologies.

Paragonix Technologies, a leading organ transplant company, announced the launch of a new donor organ courier service in partnership with Nationwide Organ Recovery Transport Alliance (NORA). This initiative is a fundamental shift in the history of organ transplantation, utilizing advanced preservation technology to provide sensitive donor organs with a cost-effective alternative of air transportation on commercial flights rather than traditional private charters. Notably, Norton Thoracic Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix was the first transplant center to utilize the new logistical support network, successfully transplanting the donor lungs without complication or delay.

Paragonix Technologies, a leading organ transplant company, announced today that it has entered into a definitive agreement to be acquired by Getinge. This strategic acquisition will enhance Getinge’s global healthcare portfolio to also address needs in solid organ transplantation. Getinge’s global reach will expand access of Paragonix’s innovative organ transplant technologies to new markets while also creating opportunities for combining the organ containment and blood perfusion technologies of the two companies for new innovations. Paragonix and Getinge share a vision to deliver market-leading solutions across the entire spectrum of transplant care.

Paragonix Technologies, a leading organ transplant company, has announced the expansion of its GUARDIAN Registry with the introduction of a new sub-study in the cardiac branch of research. This initiative will further enhance the understanding and management of post-transplant rejection, with a particular focus on molecular diagnostics. For the first time, this large scale data collection effort connects the major data sets in pre, peri, and post transplantation: donor organ data, preservation data, post-operative outcomes, survival and – uniquely – post-transplant rejection data.

Paragonix Technologies, a leading organ transplant company, announced today the first liver transplant case in which a pediatric donor liver was preserved using the LIVERguard® Donor Liver Preservation System and successfully transplanted by Dr. Deepak Vikraman at Duke University Hospital in Durham, NC. Launched in 2022, the Paragonix LIVERguard has now been used in over 300 clinical liver transplant cases across the United States, with this case being the first use in a pediatric setting.

Paragonix Technologies, a leader in organ transplant technology, proudly announces the PancreasPak™ Organ Preservation System, the first FDA-cleared device designed to protect and monitor donor pancreases during transportation. Pre-orders for this groundbreaking technology begin on June 27, 2024, with full availability slated for September 1, 2024.

Paragonix Technologies, Inc., a pioneer in organ transplant products and services, announces the landmark publication of the first clinical manuscript assessing the use of FDA-cleared advanced organ preservation technology to significantly extend ischemic times, a term referring to the sensitive window of time between organ recovery and transplantation. Prolonged periods of uncontrolled preservation can risk detrimental effects on the viability of the tissue or organ; however, safely extending ischemic times beyond fifteen hours can facilitate potential new avenues that surgeons can harness to significantly enhance access to life-saving transplants for patients. This milestone publication lays a strong foundation for future clinical applications in organ preservation and transplantation. For example, presenting a means to better accommodate longer transportation times, overnight bridging, or optimizing case scheduling during the day.

Paragonix Technologies, a pioneer in organ transplant solutions, is proud to publicly announce the recurrent success of a new, innovative strategy recently developed to minimize the complexities and logistics of placing high-risk donor livers. Pioneered in tandem with Mid-America Transplant, a leading organ procurement organization that specializes in managing organ and tissue donations, this new initiative effectively harnesses advanced liver preservation technology to utilize donor livers that would have otherwise not been accepted for use in transplantation. Notably, the renowned organ procurement organization (OPO) has successfully employed the new initiative to accommodate the workflow of multiple challenging liver transplant surgeries performed by Tampa General Hospital, recognized as the fourth largest liver transplant center in the United States.

Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication of new groundbreaking data reflecting the clinical impact of its flagship advanced preservation device, the Paragonix SherpaPak Cardiac Transport System (CTS), to protect and monitor donor hearts from extended criteria donors. In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ. The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.

Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the launch of a comprehensive network of donor organ procurement, preservation, and transportation services. This expansion includes the establishment of seven strategically located procurement hubs across the United States, designed to optimize coordination and logistics for the transplant community. These hubs, equipped to provide around-the-clock, on-demand support, comprise a team of over 50 distinguished procurement professionals, including certified surgeons and preservationists, all dedicated to advancing the field of organ transplantation.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, has successfully completed the world’s first-in-human case utilizing its newest donor lung preservation technology, the BAROguard™ Donor Lung Preservation System, which received FDA 510(k) clearance in August 2023. The groundbreaking case, conducted by Dr. Kunal Patel at Duke University Medical Center, safely protected a pair of donor lungs across 600 miles. The BAROguard™ System actively preserved and monitored the donor lungs for over 6 hours on their journey to provide a life-saving transplant.

Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations. This expansion reflects the company's continued growth and its enduring commitment to serving clinicians and patients worldwide. The facility is equipped with state-of-the-art research and development laboratories and collaborative spaces designed to foster innovation and teamwork across departments in the ever-evolving field of organ transplantation.

Paragonix Technologies, a leading organ transplant company, received US Food and Drug Administration (“FDA”) clearance for its next-generation donor lung preservation system, BAROguard™. The BAROguard™ System combines Paragonix’s existing advanced hypothermic preservation technology with automated continuous and active airway pressure control, ensuring that an optimal temperature range and a clinically recommended inflation pressure range for donor lungs are maintained throughout the journey from donor to recipient patient. This novel combination of advanced technologies further reinforces the company's ongoing commitment to improve and redefine the standard of care within transplant medicine.

Paragonix Technologies, a leading organ transplant company, announced today its collaboration with Enduring Hearts, a nonprofit organization dedicated to improving the quality of life for children living with transplanted hearts. Enduring Hearts’ Road to Recovery family program provides pediatric heart transplant families with gas gift cards to help subsidize the costs of burdensome and frequent travel to medical appointments.

Paragonix Technologies, the leading hypothermic organ preservation provider, announced today its expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation on clinical outcomes in donor organ transplant.

Paragonix Technologies announces a milestone achievement for its Paragonix LUNGguard™ System as the device safely completed a record distance for donor lung transport from Alaska to North Carolina. The longest case in terms of distance and total ischemic time for the LUNGguard Donor Lung Preservation system was completed by Duke University Hospital, one of the largest organ transplant centers in the world.

Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the first-in-human clinical use of the only FDA cleared cold storage device for donor livers, the LIVERguard™ Donor Liver Preservation System by Mayo Clinic in Florida, one of the largest Liver Transplant Centers in the United States.

Paragonix Technologies, the leading hypothermic donor organ preservation provider, announced the first-in-human clinical use of the investigational NRP-DCD Method by the University of Nebraska Medical Center to recover a donor heart and transport it utilizing the Paragonix SherpaPak® System. This novel method to advance heart transplantation utilizing DCD (donation after circulatory death) donors is an innovative combination of proven techniques developed by the University of Nebraska Medical Center to increase the distance DCD donor organs can travel, thus increasing the potential donor pool.

Paragonix Technologies, the leading provider of donor organ preservation and transport systems, announces the clinical and commercial launch of LIVERguard™ Donor Liver Preservation System in both the US and Europe, along with the launch of its clinical global registry, GUARDIAN-LIVER (Global Utilization And Registry Database for Improved preservAtion of doNor LIVERs).

Paragonix Technologies announces the launch of a new collaboration with the University of Nebraska Medical Center on a novel method to advance heart transplantation utilizing DCD (donation after circulatory death) donors. This new method is an innovative combination of proven techniques created to increase the distance DCD donor organs can travel, thus increasing the potential donor pool.

Paragonix Technologies announces the launch of its new OPTION On-Demand Preservation Services Network in the United States. OPTION is an around-the-clock rapid deployment service designed to better serve the transplant community and improve efficiencies in donor organ procurement and recovery. The first phase of the OPTION program has launched, including the establishment of a nationwide forward deployment of distributed inventory at responsive depots to ensure transplant surgeons have access to advanced hypothermic preservation technologies.

Paragonix Technologies announced a partnership with Southwest Transplant Alliance (STA) to provide advanced organ preservation technology as part of both organization’s ongoing work to save lives through organ donation and transplantation. Under this new partnership, Paragonix will provide the technology, clinical support and education on the advanced preservation capabilities delivered by the Paragonix SherpaPak® Cardiac Transport System.

Paragonix Technologies announced the presentation of the First Report of the GUARDIAN Registry1 at the International Society for Heart and Lung Transplantation 2021 Annual Meeting.